Aphria (NYSE:APHA) released its quarterly earnings data on Thursday. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02, Briefing.com reports. Aphria had a negative return on equity of 0.30% and a net margin of 5.75%. The firm had revenue of $145.70 million for the quarter, compared to the consensus estimate of $159.63 million. During the same quarter in the prior year, the company posted $0.07 earnings per share. The firm’s revenue was up 15.5% on a year-over-year basis.
Shares of Aphria stock opened at $4.65 on Friday. The company has a current ratio of 5.19, a quick ratio of 3.73 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of 51.67 and a beta of 2.19. Aphria has a 1-year low of $1.95 and a 1-year high of $6.44. The firm’s 50-day moving average price is $4.76 and its two-hundred day moving average price is $4.29.
APHA has been the topic of a number of research reports. Stifel Nicolaus upgraded Aphria from a “hold” rating to a “buy” rating and increased their price objective for the stock from $5.30 to $8.00 in a report on Monday, July 13th. Zacks Investment Research raised shares of Aphria from a “sell” rating to a “hold” rating and set a $6.25 target price for the company in a research report on Wednesday, October 7th. Pi Financial reissued a “buy” rating on shares of Aphria in a research report on Thursday, July 30th. Cantor Fitzgerald cut their price objective on shares of Aphria from $15.50 to $11.75 and set an “overweight” rating for the company in a research report on Friday. Finally, CIBC upped their price objective on shares of Aphria from $7.50 to $8.00 and gave the company an “outperform” rating in a research report on Friday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $8.61.
Aphria Inc cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands.
Recommended Story: Learning About the VIX – Volatility Index
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.